ライフサイエンスコーパス: imidazolyl

1 xyphenyl)-4,5-dihydro-4,4,5,5-tetramethyl-1H-imidazolyl-1-oxy-3-oxide (carboxy-PTIO, an NO scavenger)

2 potent compound is methyl (2E,4E,6E,8E)-9-(3-imidazolyl-2,6,6-trimethylcyclohex-1-enyl)-3,7-dimethyl

3 ymer {[Mn2(NITIm)3]ClO4}n (1) (NITImH = 2-(2-imidazolyl)-4,4,5,5-tetramethyl-4,5-dihydro-1H-3-oxide-1

4 17alpha-hydroxylase/C17,20-lyase, 17beta-(4-imidazolyl)-5-pregnen-3beta-ol, was also able to inhibit

5 ither imidazole nitrogen, 1e, a di(isopropyl)imidazolyl analogue of 1b was made along with its doubly

6 Carbohydrate-derived imidazolyl and triazolyl thiourethanes with such accepto

7 abricated based on platinum(II) bis(N-methyl-imidazolyl)benzene chloride (Pt-16).

8 addition of iodoalkanes to sodium tetrakis(1-imidazolyl)borate (NaBIm(4)).

9 zolyl)borate or hydrogen tetrakis(4-methyl-1-imidazolyl)borate in a concentrated ammonium hydroxide s

10 (3))(4)Pd(NO(3))(2)] and hydrogen tetrakis(1-imidazolyl)borate or hydrogen tetrakis(4-methyl-1-imidaz

11 ce of counterion, i.e. bromide vs tetrakis(1-imidazolyl)borate.

12 omega-Imidazolyl carboxylic acids (C10-C12) have been used as

13 ants of the modified 38C2 and the Cu(II)-bis-imidazolyl complex k(6-CuCl2) gives a rate enhancement o

14 bitors of P450(17 alpha), whereas the 17-(2'-imidazolyl) compound (9b) was one of the most potent inh

15 10-(Imidazolyl)decanoic acid was the best inhibitor (Kic = 0

16 The binding of 10-(imidazolyl)decanoic acid was too tight for an absolute K

17 omega-imidazolyl-octanoic fatty acid, omega-imidazolyl-decanoic fatty acid, and omega-imidazolyl-dod

18 We found that CLT and a stable des-imidazolyl derivative inhibited directly two pharmacolog

19 The 17 beta-(4'imidazolyl) derivatives (2a, 2e, 4a, 4c) were found to b

20 A number of 17-(4'-Imidazolyl) derivatives were prepared by condensing the

21 Among the 17-(4'-imidazolyl) derivatives, introduction of the 17 alpha-hy

22 amino acid unsymmetrical urea A and carboxy-imidazolyl-dipeptide ester B intermediates.

23 The nonpolar nature of such doubly masked imidazolyl-dipyrromethanes facilitated handling.

24 HeLa cells treated with 1-methyl-1-propyl-2-imidazolyl disulfide (IV-2), a pharmacologic inhibitor o

25 study, we hypothesized that 1-methylpropyl 2-imidazolyl disulfide (IV-2), a thioredoxin (TRX) inhibit

26 mia clonogenic cells toward 1-methylpropyl 2-imidazolyl disulfide, an inhibitor of thioredoxin expres

27 ithiocarbonate, S-methyl xanthates, methyl N-imidazolyl dithioate, N-alkyl dithiocarbamate, and pheny

28 c = 0.9 microM, Kiu = 5.7 microM), while 12-(imidazolyl)dodecanoic acid (Kic = 1.35 microM, Kiu = 6.9

29 ga-imidazolyl-decanoic fatty acid, and omega-imidazolyl-dodecanoic fatty acid.

30 c) to alkynes 2a-s to synthesize the indolyl/imidazolyl enamines 3a-p, 5a-o, and 6a-e using superbasi

31 s of these inhibitors by attaching the omega-imidazolyl fatty acid to the nitrogen of an amino acid g

32 Omega-imidazolyl fatty acids have previously been found to be

33 erocycles and the coupling of one eta(2)-N,C-imidazolyl fragment with a coordinated 1-methylbenzimida

34 ors affecting the nucleophilic attack of the imidazolyl group on the phosphorus center of the substra

35 h an effective molarity up to 2900 M for the imidazolyl group, ruling out competition from external n

36 We report that attachment of the 4-imidazolyl group, via 1-, 2-, or 3-carbon alkyl or alkan

37 CH(2)(S-tim)(2) (2) (where tim = thio(methyl)imidazolyl) has been reinvestigated in order to optimize

38 extra protein-like functionalities, namely, imidazolyl (histidine analogue) and primary amino (lysin

39 t are supported by tris(2-mercapto-1-t-butyl-imidazolyl)hydroborato ligation, namely [Tm(Bu(t))]HgEPh

40 donor moiety {D = benzyl (Bz); pyridyl (Py); imidazolyl (Im); dimethylamino (NMe(2)); (tert-butylphen

41 )bimiq1)](2+) (1c, where (Pr)bimiq1 = bis(3-(imidazolyl)isoquinolinyl)propane) emerges as a catalyst

42 hing and detaching the nitrogen atoms in its imidazolyl "legs" to and from the protruding close-packe

43 catalytic benefit to the binding of the bis-imidazolyl ligand into 38C2.

44 tions of both clotrimazole (CLT) and its des-imidazolyl metabolite, 2-chlorophenyl-bisphenyl-methanol

45 The modified nucleotides, a C5-imidazolyl-modified dUTP and 3-(aminopropynyl)-7-deaza-d

46 By using C5-imidazolyl-modified dUTPs together with 3-(aminopropynyl

47 simultaneous incorporation of both amino and imidazolyl moieties into a DNA molecule during PCR.

48 dinating heterocycles and, among them, the 4-imidazolyl moiety is the most convenient for the interac

49 described, comprising a simple divalent bis(imidazolyl) molecule that is shown to "walk" at room tem

50 analysis for this reaction a series of o-(2'-imidazolyl)naphthyl (4-nitrophenyl) phosphate isomers we

51 th apical positions occupied by the incoming imidazolyl nucleophile and the p-nitrophenolate leaving

52 analogs by cocrystallizing CYP2E1 with omega-imidazolyl-octanoic fatty acid, omega-imidazolyl-decanoi

53 ylamino]-3-[4-(1-methyl-4-trifluoromethyl -2-imidazolyl)phenoxy]-2-propanol dihydrochloride (CGP-2071

54 ylamino]-3-[4-(1-methyl-4-trifluoromethy l-2-imidazolyl)phenoxy]-2-propanol], which showed no agonist

55 hylamino]-3-[4-(1-methyl-4-trifluormet hyl-2-imidazolyl)-phenoxy]-2-propanolmethanesulfonate (CGP2071

56 hylamino]-3-[4-(1-methyl-4-trifluormet hyl-2-imidazolyl)-phenoxy]-2-propanolmethanesulphonate (CGP 20

57 tetraazacyclododedacane, tris(4,5-dimethyl-2-imidazolyl)phosphine, and tris(2-benzimidazolylmethyl)am

58 stidinol, NAD, and the alternative substrate imidazolyl propanediol demonstrated an essential base wi

59 urocanic acids), and the related fluorinated imidazolyl propenals and prop-2-en-1-ols, from urocanic

60 uence has been adapted to prepare 3-fluoro-3-imidazolyl-propenoic acids (beta-fluorourocanic acids),

61 eport the synthesis and activity of novel 17-imidazolyl, pyrazolyl, and isoxazolyl androstene derivat

62 eterocyclic substituents, including pyridyl, imidazolyl, pyrimdyl, and other groups.

63 also reveal that the respective cofragments (imidazolyl, pyrrolyl, and phenoxyl) are formed in very l

64 r phenyl group (2c) on the 2'-position of 4'-imidazolyl ring caused a dramatic decrease in the potenc

65 We show here how an imidazolyl ring incorporated into a rotary switch based

66 the substituent groups on the cross-linking imidazolyl ring strikes a perfect balance with their por

67 '-imidazolyl) ring (9a, 10) or a 20 beta-(2'-imidazolyl) ring (12), instead of the 17 beta-(4'-imidaz

68 zolyl) ring (12), instead of the 17 beta-(4'-imidazolyl) ring (2a, 4a), are weak inhibitors.

69 y properties, Compounds having a 17 beta-(2'-imidazolyl) ring (9a, 10) or a 20 beta-(2'-imidazolyl) r

70 b(5) reveals nearly orthogonal planes of the imidazolyl rings of heme-ligating residues His(89) and H

71 idin-4-yl)-1-hydroxypyrazole (4-PHP) 3- or 5-imidazolyl substituted analogues have been designed, syn

72 icroM, Kiu = 6.9 microM) was superior to 11-(imidazolyl)undecanoic acid (Kic = 7.5 microM, Kiu = 16 m